Safety of DMT with psychological support, with or without SSRIs, for depression
About this title
An open-label study investigating the safety, tolerability, pharmacokinetics, pharmacodynamics and exploratory efficacy of intravenous dosing of SPL026 drug product (N, N-dimethyltryptamine fumarate; DMT Fumarate [A Serotonergic Psychedelic]) alone or in combination with selective serotonin reuptake inhibitors in patients with major depressive disorder
Read the official source — ISRCTN10974027Understand this study
Who could participate?
This study is for people with depression. Listed age limits: 18 years to 99 years. Other eligibility criteria apply.
- Listed locations
- United Kingdom
What to know before participating
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
- Recruitment status
- Not recruiting
- Enrollment listed in the registry
- Not clearly listed
- Sponsor
- Cybin UK Ltd
- Sponsor type
- Other organization
- Study type
- Other
- Intervention type
- Other / unclear
- Locations
- United Kingdom
- Age range
- From 18 Years to 99 Years
- Official registry ID
- ISRCTN10974027
- Official title
Show the full official title
Safety, tolerability, pharmacokinetics, pharmacodynamics and exploratory efficacy of intravenous dosing of SPL026 drug product (N, N-dimethyltryptamine fumarate; DMT Fumarate [A Serotonergic Psychedelic]) alone or in combination with selective serotonin reuptake inhibitors in patients with major depressive disorder
Recruitment & locations
United Kingdom
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Cybin UK Ltd.
Who can participate?
This study is for people with depression. Listed age limits: 18 years to 99 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as not recruiting.
